We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
34 result(s) found, displaying 21 to 30
-
Prescription medicine decision summaryTGA decision: Byooviz (ranibizumab) is approved to treat visual impairment.
-
Prescription medicine registrationActive ingredients: Ranibizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONTRUZANT trastuzumab 150 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HADLIMA adalimumab (rch) 40 mg solution for injection in pre filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HADLIMA adalimumab (rch) 40 mg solution for injection in PushTouch auto-injector.
-
Prescription medicine registrationActive ingredients: adalimumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RENFLEXIS infliximab 100 mg powder for injection vial.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Adalimumab
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BRENZYS etanercept (rch) 50 mg solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BRENZYS etanercept (rch) 50 mg solution for injection auto-injector.